Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Therapeutics announced participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference, scheduled for April 25-26, 2023, in Toronto. Dr. Fahar Merchant, the President and CEO, will engage in a fireside chat on April 25 at 3:30 p.m. EDT. Investors can access the webcast here. Additionally, management will have one-on-one meetings at the event. Medicenna is focused on innovating immunotherapy treatments, including its IL-2 Superkine, MDNA11, designed to enhance cancer treatment by selectively targeting effector T cells and NK cells. The company’s bizaxofusp, an IL-4 Empowered Superkine, has been studied in clinical trials for recurrent GBM and holds FDA FastTrack and Orphan Drug status.
- None.
- None.
TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and management will participate in one-on-one meetings at the 2023 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 25-26, 2023.
Details on the fireside chat are as follows:
| 2023 Bloom Burton & Co. Healthcare Investor Conference | |
| Date: | Tuesday, April 25, 2023 |
| Time: | 3:30 p.m. EDT |
| Webcast: | https://wsw.com/webcast/bloomburton8/mdna/2717440 |
Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
FAQ
When is Medicenna participating in the Bloom Burton & Co. Healthcare Investor Conference?
What time is Medicenna's fireside chat at the conference?
What is MDNA11, developed by Medicenna?
What status does bizaxofusp hold from the FDA?
